18-year follow-up | |||||||
---|---|---|---|---|---|---|---|
Severe fatigueb | |||||||
No. assessed | Fatiguea mean ±SD | No. (%) | OR (95% CI) crude | p-value | OR (95% CI) adjustedc | p-value | |
Baseline variables | |||||||
Sex | |||||||
Male | 106 | 2.5 ±1.1 | 10 (9) | 1.0 (ref.) | – | 1.0 (ref.) | – |
Female | 271 | 3.5 ±1.5 | 89 (33) | 4.7 (2.3–9.4) | < 0.001 | 4.6 (2.3–9.3) | < 0.001 |
Onset age | |||||||
< 6y | 196 | 3.1 ±1.4 | 48 (24) | 1.0 (ref.) | – | 1.0 (ref.) | – |
≥6y | 179 | 3.3 ±1.5 | 50 (28) | 1.2 (0.8–1.9) | 0.5 | 1.1 (0.7–1.8) | 0.6 |
Diagnostic delay | |||||||
< 6 months | 304 | 3.1 ±1.4 | 72 (24) | 1.0 (ref.) | – | 1.0 (ref.) | – |
≥6 months | 41 | 3.9 ±1.7 | 18 (44) | 2.5 (1.3–4.9) | 0.007 | 2.9 (1.4–5.9) | 0.004 |
ANA | |||||||
Negative | 146 | 3.2 ±1.5 | 37 (25) | 1.0 (ref.) | – | 1.0 (ref.) | – |
Positive | 62 | 3.3 ±1.5 | 16 (26) | 1.0 (0.5–2.0) | 0.9 | 0.9 (0.5–1.9) | 0.9 |
HLA-B27 | |||||||
Negative | 217 | 3.2 ±1.5 | 55 (25) | 1.0 (ref.) | – | 1.0 (ref.) | – |
Positive | 60 | 3.4 ±1.6 | 20 (33) | 1.5 (0.8–2.7) | 0.2 | 1.7 (0.9–3.3) | 0.1 |
VAS paind | |||||||
=0 | 50 | 2.5 ±1.3 | 8 (16) | 1.0 (ref.) | – | 1.0 (ref.) | – |
> 0 | 161 | 3.4 ±1.6 | 50 (31) | 2.4 (1.0–5.4) | 0.04 | 2.2 (0.9–5.1) | 0.08 |
Cumulative active joints | |||||||
≤4 joints | 232 | 3.1 ±1.5 | 53 (23) | 1.0 (ref.) | – | 1.0 (ref.) | – |
> 4 joints | 135 | 3.4 ±1.5 | 43 (32) | 1.6 (1.0–2.5) | 0.06 | 1.5 (0.9–2.5) | 0.1 |
Variables at 8-year visit | |||||||
VAS pain | |||||||
=0 | 139 | 2.7 ±1.4 | 25 (18) | 1.0 (ref.) | – | 1.0 (ref.) | – |
> 0 | 151 | 3.5 ±1.5 | 51 (34) | 2.3 (1.3–4.0) | 0.003 | 2.3 (1.3–4.0) | 0.005 |
CHQ PhS | |||||||
≥40 | 133 | 2.9 ±1.3 | 29 (22) | 1.0 (ref.) | – | 1.0 (ref.) | – |
< 40 | 32 | 4.0 ±1.8 | 16 (50) | 3.6 (1.6–8.0) | 0.002 | 3.7 (1.5–8.9) | 0.004 |
CHQ PsS | |||||||
≥40 | 152 | 3.1 ±1.4 | 39 (26) | 1.0 (ref.) | – | 1.0 (ref.) | – |
< 40 | 13 | 3.7 ±1.9 | 6 (46) | 2.5 (0.8–7.8) | 0.1 | 2.6 (0.7–9.3) | 0.1 |
CHAQ/HAQ | |||||||
=0 | 193 | 2.9 ±1.4 | 38 (20) | 1.0 (ref.) | – | 1.0 (ref.) | – |
> 0 | 104 | 3.7 ±1.6 | 40 (38) | 2.5 (1.5–4.3) | 0.001 | 2.3 (1.3–3.9) | 0.004 |
JADAS71 | |||||||
≤1 | 96 | 2.8 ±1.2 | 16 (17) | 1.0 (ref.) | – | 1.0 (ref.) | – |
> 1 | 97 | 3.7 ±1.6 | 37 (38) | 3.1 (1.6–6.1) | 0.001 | 2.8 (1.4–5.8) | 0.004 |
DMARDs/biologicse | |||||||
No | 152 | 2.8 ±1.3 | 30 (20) | 1.0 (ref.) | – | 1.0 (ref.) | – |
Yes | 215 | 3.3 ±1.4 | 66 (31) | 1.8 (1.1–3.0) | 0.02 | 2.0 (1.2–3.3) | 0.009 |